MethylGene Inc. (TSX: MYG) today disclosed preclinical data for MGCD290, a fungal Hos2 inhibitor to be used in combination with azoles for the treatment of fungal infections. MethylGene is currently evaluating MGCD290 in a Phase I clinical trial.

MethylGene Inc. (TSX: MYG) today disclosed preclinical biomarker data for its kinase inhibitor, MGCD265, in a poster session at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva.

MethylGene Inc. (TSX: MYG) today announced that as a result of the internal voluntary suspension of enrollment of new patients into clinical trials evaluating MGCD0103, MethylGene and its development partner, Celgene Corporation, have been informed by the U.S.

MethylGene Inc. (TSX: MYG) and Celgene Corporation today announced that, at the recommendation of a standing internal safety committee, the companies are temporarily suspending enrollment of new patients into clinical trials evaluating MGCD0103.

MONTREAL, QUEBEC--(Marketwire - June 25, 2008) - MethylGene Inc.